Detailed Information on Publication Record
2007
Vaccination of myeloma patients with monoclonal immunoglobulin loaded dendritic cells: preclinical and first clinical results of a phase I/II clinical trial.
OČADLÍKOVÁ, Darina, Lenka ZAHRADOVÁ, Lucie KOVÁŘOVÁ, Jaroslav MICHÁLEK, Roman HÁJEK et. al.Basic information
Original name
Vaccination of myeloma patients with monoclonal immunoglobulin loaded dendritic cells: preclinical and first clinical results of a phase I/II clinical trial.
Name in Czech
Vakcinace pacientů s mnohočetným myelomem dendritickými buňkami loadovanými monoklonálním imunoglobulinem: preklinické a první klinické výsledky klinické studie fáze I/II.
Authors
OČADLÍKOVÁ, Darina (203 Czech Republic, guarantor), Lenka ZAHRADOVÁ (203 Czech Republic), Lucie KOVÁŘOVÁ (203 Czech Republic), Jaroslav MICHÁLEK (203 Czech Republic) and Roman HÁJEK (203 Czech Republic)
Edition
Cellular Therapy. 2007
Other information
Language
English
Type of outcome
Konferenční abstrakt
Field of Study
30200 3.2 Clinical medicine
Country of publisher
Germany
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 10.896
RIV identification code
RIV/00216224:14110/07:00023887
Organization unit
Faculty of Medicine
ISSN
UT WoS
000249533100213
Keywords in English
Multiple myeloma; Id-protein; vaccine
Tags
Tags
International impact, Reviewed
Změněno: 9/4/2010 10:26, Mgr. Darina Očadlíková, Ph.D.
V originále
Background: Adjuvant immunotherapy with antigen-loaded dendritic cells (DCs) represents a novel and relatively non-toxic treatment modality for multiple myeloma (MM). Malignant cells in MM produce a monoclonal immunoglobulin (idiotypic protein) which is considered a tumor-specific antigen and can be used for the induction of T lymphocytes. To enhance the anti-myeloma immune response, the idiotypic protein (Id-protein) can be loaded into autologous DCs and used for vaccination. Aims: The aim of this study was to evaluate DC-based vaccine preclinically and test the safety and the immune response of the vaccine in patients with MM. Patients and Methods: Pre-clinical testing was performed in 8 patients with MM. DC loaded with autologous myeloma cells were used for autologous T cell stimulation in vitro. After succesful preclinical testing, we have vaccinated 4 patients with stable disease or asymptomatic slow progressive disease according to EBMT criteria. Patients were pre-treated with high-dose chemotherapy and auto-PBSCT. DC precursors were isolated as an adherent fraction from peripheral blood of the myeloma patients. DCs were prepared in vitro and loaded with Id-protein under GMP conditions as previously described (Ocadlikova et al.Med Oncol 2006, 23: 377-384). Patients were vaccinated every 4 weeks subcutaneously with 6 doses, each containing 1,46-18,1 e 06 (mean 9,52 e 06) DCs. The immune response was evaluated by flow cytometry, Elispot and the skin test of hypersensitivity. Results: IFN-gamma production of T cells stimulated with autologous myeloma cell loaded DC was observed. After successful pre-clinical testing a clinical phase I/II trial was initiated. A total of 24 vaccines were applied to 4 patients so far (January 2007). The viability, number and functional characteristics of in vitro matured DCs loaded with Id-protein were satisfactory with 50,10-99,3% (mean 87,08%) of HLADR/CD86+ cells. Each vaccination was well tolerated with only mild fever in 1 patient. No grade II-IV. toxicity appeared. The clinical trial is ongoing and a total of 12 patients is planned to be evaluated. Conclusions: Vaccination with Id-protein loaded autologous dendritic cells demonstrates feasibility and safety in patients with multiple myeloma pre-treated with high dose chemotherapy.
In Czech
Vakcinace pacientů s mnohočetným myelomem dendritickými buňkami loadovanými monoklonálním imunoglobulinem: preklinické a první klinické výsledky klinické studie fáze I/II.
Links
| LC06027, research and development project |
|